ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 3076 • 2015 ACR/ARHP Annual Meeting

    Interferon Gamma (IFNg) Is the Driving Mediator of Secondary Hemophagocytic Lymphohistiocytosis (sHLH) in TLR9-Mediated Pathogenesis in Mice and Is Correlated to Disease Parameters in Children

    Cristina De Min1, Vanessa Buatois1, Laurence Chatel1, Laura Cons2, Francoise Richard3, Claudia Bracaglia4, Fabrizio De Benedetti5, Marie Kosco-Vilbois1 and Walter Ferlin1, 1NovImmune S.A., Geneva, Switzerland, 2NovImmune S.A., Plan-Les-Ouates, Geneva, Switzerland, 3NovImmune SA, Geneva, Switzerland, 4Pediatric Medicine, Division of Rheumatology, Rome, Italy, 5Division of Rheumatology, Department of Pediatric Medicine, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy

    Background/Purpose: Life-threatening hyperinflammatory syndromes caused by severe hypercytokinemia include primary (p) and secondary (s) hemophagocytic lymphohistiocytosis (HLH). Increased circulating levels of interferon gamma (IFNg) in…
  • Abstract Number: 3077 • 2015 ACR/ARHP Annual Meeting

    Anakinra in Patients with Cortico-Dependent Idiopathic Recurrent Pericarditis: A Randomised Double-Blind Placebo-Controlled Withdrawal Trial

    Antonio Brucato1, Massimo Imazio2, Silvia Maestroni1, Davide Faustino Cumetti3, Anna Valenti1, Renzo Marcolongo4, George Lazaros5, Mara Carraro2, Fiorenzo Gaita2, Gian Luca Erre6, Martina Finetti7, Marco Gattorno7 and Alberto Martini8, 1Internal Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy, 2Cardiology, Maria Vittoria Hospital, Torino, Italy, 3Internal Medicine, Internal Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy, 4Clinical Immunology, Hospital of Padova, Padova, Italy, 5Department of Cardiology, Hippokration General Hospital, Athens, Greece, 6Rheumatology, Hospital of Sassari, Sassari, Italy, 7Pediatry, G. Gaslini Institute, Genova, Italy, 8Istituto G. Gaslini, Pediatria II, PRINTO, and University of Genoa, Genoa, Italy

    Background/Purpose: Patients with recurrent pericarditis either do not respond or are intolerant to treatment with NSAIDs drugs, corticosteroids and colchicine. We aimed to assess the…
  • Abstract Number: 3078 • 2015 ACR/ARHP Annual Meeting

    ABCG2 rs2231142 predicts Poor Response to Allopurinol in Patients with Gout

    Lisa K. Stamp1, Mary Wallace2, Tony R. Merriman3, Amanda Phipps-Green4, Ruth Topless4,5, Jill Drake6, Paul Tan7, Nicola Dalbeth8 and Rebecca Roberts4, 1Medicine, University of Otago, Christchurch, Christchurch, New Zealand, 2Surgical Sciences, University of Otago, Dunedin, New Zealand, 3Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, 4University of Otago, Dunedin, New Zealand, 5Department of Biochemistry, University of Otago, Dunedin, New Zealand, 6Rheumatology, Immunology and Allergy, Christchurch Hospital, Christchurch, New Zealand, 7University of Auckland, Auckland, New Zealand, 8Department of Medicine, University of Auckland, Auckland, New Zealand

    Background/Purpose: Many patients fail to reach target serum urate (SU) on allopurinol. Although the most common causes of inadequate response are non-adherence and low dosing…
  • Abstract Number: 3079 • 2015 ACR/ARHP Annual Meeting

    Efficacy and Safety of Riociguat in Patients with Pulmonary Arterial Hypertension (PAH) Associated with Connective Tissue Disease (CTD)

    Christopher P. Denton1, J. Gerry Coghlan2, Hossein-Ardeschir Ghofrani3, Friedrich Grimminger3, Jianguo He4, Gabriela Riemekasten5, Dario Vizza6, Annette Boeckenhoff7, Christian Meier8, Janethe de Oliveira Pena9 and Marc Humbert10, 1Centre for Rheumatology and Connective Tissue Disease, UCL Medical School Royal Free Campus, London, United Kingdom, 2Royal Free London NHS Foundation Trust, London, England, 3University of Giessen and Marburg Lung Center, Giessen, Germany, 4Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 5Clinic of Rheumatology and Clinical Immunology, Berlin, Germany, 6La Sapienza University of Rome, Rome, Italy, 7Bayer Pharma AG, Wuppertal, Germany, 8Bayer Pharma AG, Berlin, Germany, 9Bayer HealthCare Pharma, Whippany, NJ, 10Université Paris-Sud, Laboratoire d’Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM Unité 999, Le Kremlin–Bicêtre, France

    Background/Purpose: PAH associated with CTD (PAH-CTD) has a worse prognosis than idiopathic/familial PAH. Here we report a prospective subgroup analysis of patients with PAH-CTD from…
  • Abstract Number: 3080 • 2015 ACR/ARHP Annual Meeting

    Histone H2AX Phosphorylation As a Measure of DNA Double Strand Breaks and a Marker of Environmental Stress and Disease Activity in Lupus

    Rajaie Namas, Paul Renauer, Mikhail Ognenovski, Pei-Suen Tsou and Amr H. Sawalha, Division of Rheumatology, University of Michigan, Ann Arbor, MI

    Background/Purpose: Studies suggested that defective or inefficient DNA double strand break (DSB) repair results in failure to preserve genomic integrity leading to apoptotic cell death,…
  • Abstract Number: 3081 • 2015 ACR/ARHP Annual Meeting

    IRF5 Deletion Prevents the SLE-like Disease Initiated By Dendritic Cell-Specific Loss of Caspase 8

    Carla M. Cuda1 and Harris R. Perlman2, 1Rheumatology, Northwestern University, Chicago, IL, 2Feinberg School of Medicine, Northwestern University, Chicago, IL

    Background/Purpose:  Previous studies implicate dendritic cells (DCs) in the initiation and persistence of systemic lupus erythematosus (SLE).  While DCs from SLE patients exhibit elevated activation,…
  • Abstract Number: 3082 • 2015 ACR/ARHP Annual Meeting

    Nanogel Based Delivery of an Inhibitor of Calcium/ Calmodulin- Dependent Protein Kinase 4 Suppresses Experimental Autoimmune Encephalomyelitis and Lupus-like Disease in Mice

    Kotaro Otomo1, Tomohiro Koga2, Nobuya Yoshida3, Masayuki Mizui4, Christina Kriegel5, Tarek Fahmy6 and George C. Tsokos3, 1Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 2Department of Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan, 3Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 4Department of Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan, 5Department of Biomedical Engineering, Yale University, New Heaven, CT, 6Biomedical and Chemical Engineering, Yale University, New Heaven, CT

    Background/Purpose: Treatment of autoimmune diseases is still based on the use of general immunosuppressive drugs which invariably cause severe side effects. This fact has compelled…
  • Abstract Number: 3083 • 2015 ACR/ARHP Annual Meeting

    Antibody Array Based Proteomic Screening of 274 Serum Markers in Systemic Lupus Erythematosus

    Tianfu Wu1, Huihua Ding2, Cristina Arriens3, Chungwen Wei4, Jennifer H. Anolik5, David R. Karp3, Nancy J. Olsen6, Michelle Petri7, Ignacio Sanz4, Ramesh Saxena8 and Chandra Mohan2, 1Department of Biomedical Engineering, University of Houston, Houston, TX, 2Biomedical Engineering, University of Houston, Houston, TX, 3Internal Medicine - Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, 4Rheumatology, Emory University, Atlanta, GA, 5University of Rochester Medical Center, Rochester, NY, 6Divsion of Rheumatology, Department of Medicine, Penn State MS Hershey Medical Center, Hershey, PA, 7Rheumatology, Johns Hopkins University Hospital, Baltimore, MD, 8Nephrology, University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Given that early detection of renal involvement in systemic lupus erythematosus (SLE) and prompt management of the disease can have a significant impact on…
  • Abstract Number: 3084 • 2015 ACR/ARHP Annual Meeting

    Progression of Lupus Pathology Is Correlative with Cardiac Magnetic Resonance Imaging Abnormalities, Diminished Function, and Inflammatory Histopathology in an Animal Model

    Nicholas Young1, Jeffrey Hampton1, Saba Aqel1, Jessica Pyles2, Anna Bratasz2, Anuradha Kalyanasundaram3, Wael N. Jarjour4 and Stacy P. Ardoin5, 1Immunology and Rheumatology, The Ohio State University Medical Center, Columbus, OH, 2Small Animal Imaging Core, The Ohio State University Medical Center, Columbus, OH, 3Physiology and Cell Biology, The Ohio State University Medical Center, Columbus, OH, 4Department of Internal Medicine, Division of Immunology and Rheumatology, The Ohio State University Medical Center, Columbus, OH, 5Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease causing inflammation throughout the body and cardiovascular involvement is a significant contributor to morbidity and mortality…
  • Abstract Number: 3085 • 2015 ACR/ARHP Annual Meeting

    Platelet Activation and Endothelial Reactivity in the Pathogenesis of Tissue Inflammation/Injury in Systemic Lupus Erythematosus

    Robert Clancy1, Sokha Nhek2, Jonathan Newman3, Janet Nwaukoni1, Sara Rasmussen4, Jill P. Buyon1, Maya Rubin5, Kristen Lee1 and Jeffrey Berger5, 1Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 2New York University School of Medicine, New York, NY, 3Medicine, New York University School of Medicine, New York, NY, 4Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 5Medicine, Division of Cardiology, New York University School of Medicine, New York, NY

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk for widespread endothelial dysfunction, vascular thromboses, and premature cardiovascular disease.  Enhanced platelet activation and…
  • Abstract Number: 3086 • 2015 ACR/ARHP Annual Meeting

    The Same Multidimensional Patient Health Assessment Questionnaire Used to Assess RAPID3 in Rheumatoid Arthritis, Osteoarthritis and Other Rheumatic Diseases Can Provide Quantitative Clues to Recognize and Document Comorbid Fibromyalgia

    Kathryn A. Gibson1, Annie Huang2 and Theodore Pincus2, 1Liverpool Hospital, Liverpool, Australia, 2Rheumatology, Rush University Medical Center, Chicago, IL

    Background/Purpose: An MDHAQ/RAPID3 (Multidimensional Health Assessment Questionnaire/Routine Assessment of Patient Index Data) is a 2 sided, 1 page questionnaire which is completed by patients in…
  • Abstract Number: 3087 • 2015 ACR/ARHP Annual Meeting

    Cell Bound Complement Activation Products in Multianalyte Assay with Algorithm Have Utility in Distinguishing Primary Fibromyalgia from Systemic Lupus Erythematosus

    Daniel Wallace1, Stuart L. Silverman2, Derren Barken3, John Conklin4 and Thierry Dervieux5, 1Cedars-Sinai/UCLA, Los Angeles, CA, 2OMC Clinical Research Center, Beverly Hills, CA, 3Exagen Diagnostics, Vista, CA, 41261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, 5Research and Development, Exagen Diagnostics, Vista, CA

    Background/Purpose : Our objective was to prospectively establish the performance characteristics of a cell bound complement activation products (CB-CAPS) in a multi-analyte assay with algorithm…
  • Abstract Number: 3088 • 2015 ACR/ARHP Annual Meeting

    Genome Wide Expression Analyses Reveal Potentially Novel Drug Targets in Fibromyalgia

    Kim Jones1, Robert Bennett2,3 and Sunil Kurian4, 1Rsch & Develop/Mail Code SN OR, Oregon Health Sciences Univ, Portland, OR, 2SN-Office of Research & Development, Oregon Health & Science Univ, Portland, OR, 3Medicine & Nursing, Oregon Health & Science Univ, Portland, OR, 4The Scripps Research Institute, La Jolla, CA

    Background/Purpose: Currently there are three drugs approved by the FDA for the treatment of fibromyalgia (FM), and there appears to be a paucity of drugs…
  • Abstract Number: 3089 • 2015 ACR/ARHP Annual Meeting

    Evaluation of Learned Helplessness, Perceived Self-Efficacy and Functional Capacity in Patients with Fibromyalgia and Rheumatoid Arthritis

    Sebastian Moyano1, Marina Scolnik1, Facundo Vergara1, Maria Victoria Garcia2, Mirtha Sabelli3, Javier Rosa4 and Enrique R. Soriano5, 1Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, 2Internal Services, Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, 3Cabrera 2964 Piso 6, Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, 4Rheumatology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 5Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

    Background/Purpose: Chronic diseases involve cognitive and emotional aspects of patients. One relevant cognitive factor is the learned helplessness (LH), defined as an inadequate perception of…
  • Abstract Number: 3090 • 2015 ACR/ARHP Annual Meeting

    Fibromyalgia Predicts Two-Year Changes in Functional Status in Rheumatoid Arthritis Patients

    Hyein Kim1, Jing Cui2, M Frits3, C Iannaccone4, Jonathan S. Coblyn3, N Shadick5, Michael Weinblatt4 and Yvonne C. Lee6, 1Western University, London, ON, Canada, 2Division of Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA, 3Brigham & Women's Hospital, Boston, MA, 4Brigham and Women's Hospital, Boston, MA, 5Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 6Rheumatology Immunology & Allergy, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: The prevalence of fibromyalgia (FM) is 10-20% in rheumatoid arthritis (RA) patients, compared to 2-3% in the general population. Previous studies have shown that…
  • « Previous Page
  • 1
  • …
  • 1675
  • 1676
  • 1677
  • 1678
  • 1679
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology